MY163074A - Formulations comprising methylthioninium chloride - Google Patents
Formulations comprising methylthioninium chlorideInfo
- Publication number
- MY163074A MY163074A MYPI2013001934A MYPI2013001934A MY163074A MY 163074 A MY163074 A MY 163074A MY PI2013001934 A MYPI2013001934 A MY PI2013001934A MY PI2013001934 A MYPI2013001934 A MY PI2013001934A MY 163074 A MY163074 A MY 163074A
- Authority
- MY
- Malaysia
- Prior art keywords
- formulations
- methylthioninium chloride
- dosage forms
- mtc
- solid dosage
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
- C07D279/18—[b, e]-condensed with two six-membered rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41816410P | 2010-11-30 | 2010-11-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY163074A true MY163074A (en) | 2017-08-15 |
Family
ID=45418703
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2013001934A MY163074A (en) | 2010-11-30 | 2011-11-30 | Formulations comprising methylthioninium chloride |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9192611B2 (enExample) |
| EP (1) | EP2645994B1 (enExample) |
| JP (1) | JP6093707B2 (enExample) |
| CN (1) | CN103379901B (enExample) |
| AU (1) | AU2011334679B2 (enExample) |
| CA (1) | CA2818068C (enExample) |
| ES (1) | ES2655492T3 (enExample) |
| MY (1) | MY163074A (enExample) |
| SG (2) | SG190406A1 (enExample) |
| WO (1) | WO2012072977A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014153444A (ja) * | 2013-02-06 | 2014-08-25 | Konica Minolta Inc | 位相差フィルム、偏光板及び液晶表示装置 |
| PL3487505T3 (pl) | 2016-07-25 | 2023-10-09 | Wista Laboratories Ltd. | Podawanie i dawkowanie diaminofenotiazyn |
| FR3104438B1 (fr) | 2019-12-12 | 2021-11-19 | Univ Bordeaux | Formulation pour le bleu de methylene et procede |
| CA3257856A1 (en) | 2022-05-31 | 2023-12-07 | Wista Laboratories Ltd. | TREATMENT OF NEURODEGENERATIVE DISORDERS USING COMPOUNDS CONTAINING METHYLTHIONINIUM (MT) |
| WO2024063700A1 (en) | 2022-09-21 | 2024-03-28 | Yin Sze Loh | Oral formulation of diaminophenothiazines and methods of making and using the same in the treatment and/or prevention of diseases |
| GB202500018D0 (en) | 2025-01-02 | 2025-02-19 | Wista Lab Ltd | Long term dosing of neurodegenerative disorders utilising methylthioninium (mt) containing compounds |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4880373A (en) | 1988-04-28 | 1989-11-14 | The Upjohn Company | Tablet press |
| JPH0840942A (ja) * | 1994-07-29 | 1996-02-13 | Kanegafuchi Chem Ind Co Ltd | 薬物放出制御製剤 |
| GB9506197D0 (en) | 1995-03-27 | 1995-05-17 | Hoffmann La Roche | Inhibition of tau-tau association. |
| GB0101049D0 (en) | 2001-01-15 | 2001-02-28 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
| GB0106953D0 (en) | 2001-03-20 | 2001-05-09 | Univ Aberdeen | Neufofibrillary labels |
| GB0322756D0 (en) | 2003-09-29 | 2003-10-29 | Univ Aberdeen | Methods of chemical synthesis |
| WO2006032879A2 (en) | 2004-09-23 | 2006-03-30 | Wista Laboratories Ltd. | Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (mtc) |
| JP5186212B2 (ja) * | 2004-09-23 | 2013-04-17 | ウィスタ ラボラトリーズ リミテッド | メチルチオニニウム塩化物（ｍｔｃ）などのジアミノフェノチアジニウム化合物を化学合成および精製する方法 |
| EP2039349A1 (en) * | 2004-10-19 | 2009-03-25 | KRKA, tovarna zdravil, d.d., Novo mesto | Solid pharmaceutical composition comprising donepezil hydrochloride |
| CN101304731B (zh) * | 2005-08-24 | 2012-06-20 | 惠氏公司 | 醋酸苯卓昔芬制剂及其生产方法 |
| WO2007081367A1 (en) * | 2006-01-05 | 2007-07-19 | Teva Pharmaceutical Industries Ltd. | Dry formulations of aripiprazole |
| CN104119294B (zh) | 2006-03-29 | 2018-10-30 | 维斯塔实验室有限公司 | 3,7-二氨基-10h-吩噻嗪化合物的制备方法 |
| US20080317678A1 (en) * | 2007-06-22 | 2008-12-25 | Szymczak Christopher E | Laser Marked Dosage Forms |
| PT2954932T (pt) | 2007-10-03 | 2018-12-12 | Wista Lab Ltd | Utilização terapêutica de diaminofenotiazinas |
| CN101911081A (zh) | 2007-11-05 | 2010-12-08 | 维斯塔实验室有限公司 | 用于临床试验的体系 |
| WO2011036561A2 (en) * | 2009-09-24 | 2011-03-31 | Wis Ta Laboratories Ltd. | Process |
-
2011
- 2011-11-30 ES ES11802119.5T patent/ES2655492T3/es active Active
- 2011-11-30 SG SG2013040357A patent/SG190406A1/en unknown
- 2011-11-30 US US13/989,953 patent/US9192611B2/en active Active
- 2011-11-30 JP JP2013541414A patent/JP6093707B2/ja active Active
- 2011-11-30 SG SG10201602111VA patent/SG10201602111VA/en unknown
- 2011-11-30 EP EP11802119.5A patent/EP2645994B1/en active Active
- 2011-11-30 CN CN201180057700.9A patent/CN103379901B/zh active Active
- 2011-11-30 MY MYPI2013001934A patent/MY163074A/en unknown
- 2011-11-30 WO PCT/GB2011/001662 patent/WO2012072977A2/en not_active Ceased
- 2011-11-30 AU AU2011334679A patent/AU2011334679B2/en not_active Ceased
- 2011-11-30 CA CA2818068A patent/CA2818068C/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2011334679B2 (en) | 2016-12-15 |
| US9192611B2 (en) | 2015-11-24 |
| SG190406A1 (en) | 2013-06-28 |
| CN103379901B (zh) | 2018-04-03 |
| WO2012072977A8 (en) | 2012-09-20 |
| WO2012072977A2 (en) | 2012-06-07 |
| EP2645994B1 (en) | 2017-11-01 |
| JP6093707B2 (ja) | 2017-03-08 |
| AU2011334679A1 (en) | 2013-07-18 |
| CA2818068C (en) | 2019-06-11 |
| EP2645994A2 (en) | 2013-10-09 |
| US20130243858A1 (en) | 2013-09-19 |
| CA2818068A1 (en) | 2012-06-07 |
| SG10201602111VA (en) | 2016-04-28 |
| ES2655492T3 (es) | 2018-02-20 |
| JP2013544272A (ja) | 2013-12-12 |
| WO2012072977A3 (en) | 2012-08-16 |
| CN103379901A (zh) | 2013-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201500316B (en) | Novel compound with effects of thrombolysis, free radical scavenging and thrombus-targeting as well as preparation method and use thereof | |
| MX2013001677A (es) | Formulaciones estables de linaclotida. | |
| MX338515B (es) | Derivados de tetrahidroquinolina utiles como inhibidores de bromodominio. | |
| GB201106750D0 (en) | Novel compounds | |
| GB2492305A (en) | Polymers of benzodithiophene and their use as organic semiconductors | |
| PH12012501346A1 (en) | Heteroaryl compounds and uses thereof | |
| SG195086A1 (en) | Compounds containing hydrido-tricyano-borate anions | |
| EP2832745A4 (en) | HIGH-PURITY CYCLOPEPTIDE COMPOUND AND PROCESS FOR THE PREPARATION AND USE THEREOF | |
| PL2550018T3 (pl) | Kompozycje i sposoby użyteczne do stabilizowania preparatów zawierających białko | |
| IL227626A0 (en) | A compound of 17-il and γ-ifn inhibitors, preparations containing them and their uses | |
| ZA201209539B (en) | Compositions and methods containing alkylgycosides for stabilizing protein-containing formulations | |
| PH12013501437A1 (en) | Azetidine derivatives useful for the treatment of metabolic and inflammatory diseases | |
| SG10201706643XA (en) | Formulations and methods for nutrient delivery | |
| IN2014KN00892A (enExample) | ||
| WO2012072977A8 (en) | Formulations comprising methylthioninium chloride | |
| IN2012DN03404A (enExample) | ||
| IL221244A (en) | A tricyclic indazole compound, a method of preparation and a pharmaceutical composition containing it | |
| IN2014KN00893A (enExample) | ||
| WO2012024634A3 (en) | Environmentally-responsive nanocomposites and methods of their use | |
| MX2014006201A (es) | Formas de dosificaciones solidas de imatinib reconstituidas justo antes de usarse. | |
| MX367773B (es) | Forma salina sólida de la alfa-6-mpeg6-o-hidroxicodona como agonistas opioides y sus usos. | |
| SMT201900335T1 (it) | Composizioni e metdoi per ridurre la capacita' riproduttiva di ratti femmina | |
| ZA201209395B (en) | Trisaccharide derivates,and their use as adjuvants | |
| UA92872C2 (ru) | Комбинированное антиагрегантное и антиоксидантное лекарственное средство | |
| UA96048C2 (ru) | Применение антагониста рецепторов интерлейкина-1 как средства фригопротекторного действия |